trending Market Intelligence /marketintelligence/en/news-insights/trending/td0_pdnrb6fve3mt5zyhka2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers blood cancer drug meets main goal in midstage trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bristol-Myers blood cancer drug meets main goal in midstage trial

Bristol-Myers Squibb Co. said a combination of its drug Empliciti met its main goal in a phase 2 study for treating certain patients with multiple myeloma, a type of blood cancer.

SNL Image

Under the Eloquent-3 trial, adding Empliciti to Celgene Corp.'s Pomalyst and low-dose dexamethasone significantly extended the lives of multiple myeloma patients while keeping their disease at bay — a metric known as progression-free survival — compared to patients who were treated with Pomalyst and dexamethasone alone.

Patients under the study had multiple myeloma that either came back or did not respond to therapy. The patients also received two prior therapies, including lenalidomide and a proteasome inhibitor.

Patients receiving the Empliciti combination had a 46% reduction in the risk of their disease progressing compared to those who were treated with Pomalyst, or pomalidomide, and dexamethasone alone. Median progression-free survival for those treated with the Empliciti combination was 10.3 months, compared to 4.7 months for the other patient group.

Meanwhile, 53% of patients receiving the Empliciti combination had a reduction in their cancers, compared to 26% of patients who received pomalidomide and dexamethasone.